New pill could slow deadly lung scarring – early trial underway

NCT ID NCT05571059

Recruiting now Disease control Sponsor: Cumberland Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether an oral drug called ifetroban can slow the decline in lung function for people with idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease. About 128 adults aged 40 and older with IPF will receive either ifetroban or a placebo daily for 52 weeks. The main goal is to see if ifetroban reduces the drop in forced vital capacity (a measure of lung volume) compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ifetroban
What this could lead to: If it works, this could point toward a new oral treatment to slow lung function decline in people with idiopathic pulmonary fibrosis.
What could go wrong: This is an early Phase 2 trial with only 128 participants, so results may not confirm benefit. The drug may not slow disease progression or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

Avera Research Institute
RECRUITING

Sioux Falls, South Dakota, 57108, United States
Baylor University Medical Center
RECRUITING

Dallas, Texas, 75246, United States
Beaumont Hospital, Royal Oak
RECRUITING

Royal Oak, Michigan, 48073, United States
Bend Memorial Hospital
RECRUITING

Bend, Oregon, 97701, United States
Biosolutions Clinical Research
RECRUITING

La Mesa, California, 91942, United States
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Indiana University Health
RECRUITING

Indianapolis, Indiana, 46202, United States
Mayo Clinic Jacksonville
RECRUITING

Jacksonville, Florida, 32224, United States
Miami VA Health System
RECRUITING

Miami, Florida, 33125, United States
Northwestern Medicine
RECRUITING

Chicago, Illinois, 60611, United States
Premier Pulmonary Critical Care and Sleep Medicine
RECRUITING

Denison, Texas, 75020, United States
Pulmonary & Sleep Specialists
RECRUITING

Dickson, Tennessee, 37055, United States
Temple University Hospital
RECRUITING

Philadelphia, Pennsylvania, 19140, United States
UNC Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27514, United States
UW Health University Hospital
RECRUITING

Madison, Wisconsin, 53792, United States
University of California San Francisco
RECRUITING

San Francisco, California, 94143, United States
University of Kansas
RECRUITING

Kansas City, Kansas, 66160, United States
University of Louisville
RECRUITING

Louisville, Kentucky, 40202, United States
University of Rochester
RECRUITING

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.